Henrich Timothy J, Deeks Steven G, Pillai Satish K
Division of Experimental Medicine.
Positive Health Program, and.
J Infect Dis. 2017 Mar 15;215(suppl_3):S134-S141. doi: 10.1093/infdis/jiw648.
One of the major barriers to the successful design and implementation of human immunodeficiency virus (HIV) curative strategies is the limited ability to sensitively, specifically, and precisely quantify and characterize the whole-body burden of replication-competent HIV in individuals on effective antiretroviral therapy. Here, we review the development and validation of assays that directly and indirectly measure the size and distribution of the reservoir in blood and tissues. We also discuss the role that treatment interruptions will have in validating these assays and ultimately as a "proof of cure."
成功设计和实施人类免疫缺陷病毒（HIV）治愈策略的主要障碍之一，是在接受有效抗逆转录病毒治疗的个体中，灵敏、特异且精确地定量和表征具有复制能力的HIV全身负荷的能力有限。在此，我们综述了直接和间接测量血液及组织中病毒储存库大小和分布的检测方法的开发与验证。我们还讨论了治疗中断在验证这些检测方法以及最终作为“治愈证据”方面将发挥的作用。
